Perioperative pembrolizumab demonstrates clinical benefit in locally advanced HNSCC Summary Perioperative pembrolizumab, combining neoadjuvant and adjuvant immunotherapy around surgery, shows promising clinical benefit in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). Read More
Second-line tarlatamab improves OS in SCLC Summary Second-line treatment with tarlatamab, a DLL3-targeting bispecific T-cell engager, significantly improved overall survival (OS) in patients with relapsed or refractory small cell lung cancer (SCLC) compared to Read More
Adding durvalumab to perioperative FLOT improves gastric cancer outcomes Summary Adding the immunotherapy drug durvalumab to the standard perioperative chemotherapy regimen FLOT significantly improves outcomes for patients with resectable gastric or gastroesophageal junction cancer. The Read More
1 Million+ Views and Counting..!
Now, it has been 6 years since it was launched in late July 2018 and is moving forward. Appreciate all the respected visitors! Please share this site with your friends to push science forward and improve human health.
